<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822548</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005399-32</org_study_id>
    <nct_id>NCT01822548</nct_id>
  </id_info>
  <brief_title>Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes</brief_title>
  <official_title>Randomized, Open Label, Two Parallel Arms, Intervention Trial Comparing the Effect of DPP-IV Inhibitor Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number in Patients With Type 2 Diabetes in Metformin Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Parma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Dipeptidyl peptidase (DPP) -IV
      inhibitor Vildagliptin vs. Glibenclamide on circulating endothelial progenitor cells (EPCs)
      number in type 2 diabetes patients in metformin failure. Subjects will be followed for 12
      months after randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic patients show a higher cardiovascular risk compared with non-diabetic patients. It
      is therefore crucial that blood glucose lowering drugs reveal a favorable cardiovascular risk
      profile independently of metabolic control.

      EPCs are a subset of circulating mononuclear cells derived from the bone marrow. EPCs play a
      fundamental role in the formation of new blood vessels (neo-endothelization) and repairing of
      existing blood vessels (re-endothelization) in order to maintain endothelial homeostasis and
      integrity. Endothelial damage and tissue ischemia, through the release of growth factors and
      cytokines, represent a strong stimulus for the mobilization of EPCs from the bone marrow.
      Reduced EPC number has been related to the presence of traditional risk factors for
      cardiovascular disease and to the development of atherosclerosis and has been shown to
      predict cardiovascular (CV)risk. Type 2 diabetes is known to be associated with an increased
      CV risk and a reduced EPC number. Recent data suggest that DPP-IV inhibitors might be
      involved in the mechanisms promoting bone-marrow EPC mobilization. This putative ancillary
      effect of DPP-IV might have a favorable impact on type 2 diabetes, a condition characterized
      by an increased CV risk.

      This is a randomized, open-label, active-treatment-controlled, two parallel arm (2:1),
      intervention trial comparing DPP-IV inhibitor Vildagliptin (100 mg daily) with Glibenclamide
      (maximum daily dose of 10 mg). Treatment allocation and titration regimens are not blinded.

      Primary end-point:Absolute change in the EPC number at visit: V0 (randomization), V2 (month
      4), V3 (month 8) and V4 (month 12).

      Secondary end-point: Absolute change in HbA1C compared to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in the Endothelial Progenitor Cell (EPC) Number</measure>
    <time_frame>V0, V2 (month 4), V4 (12 month)</time_frame>
    <description>The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in HbA1C Compared to Baseline</measure>
    <time_frame>V0 (randomization), V2 (month4), V4 (month 12).</time_frame>
    <description>The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Vildagliptin &amp; metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glibenclamide &amp; metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>100 mg daily</description>
    <arm_group_label>Vildagliptin &amp; metformin</arm_group_label>
    <other_name>LAF237A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glibenclamide</intervention_name>
    <description>2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
    <arm_group_label>Glibenclamide &amp; metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)</description>
    <arm_group_label>Vildagliptin &amp; metformin</arm_group_label>
    <arm_group_label>Glibenclamide &amp; metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or above 35 years;

          -  Diagnosis of type 2 diabetes mellitus as defined by the American Diabetes Association
             , with at least one year of disease duration at the time of the screening visit;

          -  Blood glucose lowering treatment with Metformin alone (monotherapy) at a stable dose
             of at least 1.5 g/day (or maximum tolerated dose) in the 3 months prior to the
             screening visit;

          -  Insufficient metabolic control as defined by recent (last six months) HbA1c ≥ 7% in
             any peripheral laboratory and confirmed at the time of the screening;

          -  Absence of a recent clinically-relevant progression of micro- and macro-vascular
             complications (see exclusion criteria);

          -  Written informed consent to participate to the study.

        Exclusion criteria:

          -  Age below 35 years

          -  Type 1 diabetes or other causes of diabetes (pancreatectomy, gestational diabetes,
             etc.)

          -  HbA1c &lt; 7% or ≥ 9% at the screening visit

          -  Treatment with any blood glucose lowering treatment other than Metformin in the six
             months before screening visit

          -  BMI &lt; 20 or ≥ 40 kg/m2, or current/ past history of clinically-relevant eating
             disorders (including -but no limited to- nervous anorexia, bulimia, binge-eating
             disorders, etc.)

          -  Significant progression of diabetic macro-angiopathy or cardiovascular disease in the
             six months prior to study visit

          -  Significant progression of diabetic micro-angiopathy in the six months prior to study
             visit

          -  Organ failure or other severe diseases limiting life expectancy;

          -  Beginning, in the three months before screening visit, of any kind of drug which can
             modify glycemic levels (beta-blockers, diuretics…), or acute disease (acute infection,
             urinary tract infection…) in three months before screening visit

          -  History of inflammatory/infective/autoimmune chronic disease

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, gastric
             surgery, inflammatory bowel disease;

          -  Any clinically significant abnormality identified on physical examination, laboratory
             tests, ECG or vital signs at screening that in the judgment of the investigator would
             preclude safe completion of the study;

          -  Uncontrolled or inadequately controlled hypertension at screening (Systolic Blood
             Pressure (SBP)&gt;190 or Diastolic Blood Pressure (DBP) &gt;100 mmHg)

          -  Ongoing pregnancy or absence of effective contraception in women with childbearing
             potential

          -  Contraindications to the maintenance of the background therapy (Metformin), including
             -but not limited to- chronic kidney failure or plasma creatinine concentrations &gt; 1.5
             mg/dL, severe respiratory failure, etc.;

          -  Contraindications to the use of a Sulfonylurea;

          -  Contraindications to the use of a DPP-IV Inhibitor;

          -  Laboratory findings, or other disease conditions, at the screening visit that might
             interfere with study measurements:

               1. Hemoglobinopathy known to affect HbA1c assays;

               2. Known chronic liver diseases, including HBV (hepatitis B virus) and HCV
                  (hepatitis C virus) infection;

               3. Liver makers (aspartate transaminase (AST), alanine aminotransferase (ALT),
                  alkaline phosphatase (ALP), Gamma-glutamyltransferase (GGT) , bilirubin) above 2
                  times the upper normal limit;

               4. Amylase and/or lipase above 2 times the upper normal limit;

          -  Chronic use of systemic and/or inhaled corticosteroids (only topical corticosteroids
             are allowed);

          -  History of low compliance, clinically-relevant psychiatric disorders or any current/
             historical finding suggesting the patient as inappropriate to follow the study
             procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Zavaroni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera-Universitaria di Parma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Opedaliera-Universitaria</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Parma</investigator_affiliation>
    <investigator_full_name>Ivana Zavaroni</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>EPC</keyword>
  <keyword>diabetes</keyword>
  <keyword>DPP IV inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals with type 2 diabetes were recruited in the outpatient Diabetes Unit of Parma University Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vildagliptin &amp; Metformin</title>
          <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Vildagliptin: 100 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Glibenclamide &amp; Metformin</title>
          <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Glibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">Received allocated intervention n=38 Did not receive allocated intervention (only metformin) n=2</participants>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vildagliptin &amp; Metformin</title>
          <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Vildagliptin: 100 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Glibenclamide &amp; Metformin</title>
          <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Glibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="9"/>
                    <measurement group_id="B2" value="63" spread="10"/>
                    <measurement group_id="B3" value="62" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" lower_limit="26.8" upper_limit="32.9"/>
                    <measurement group_id="B2" value="28.9" lower_limit="25.4" upper_limit="34.1"/>
                    <measurement group_id="B3" value="29.0" lower_limit="26.2" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBA1C</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" lower_limit="7.4" upper_limit="7.9"/>
                    <measurement group_id="B2" value="7.7" lower_limit="7.5" upper_limit="8.1"/>
                    <measurement group_id="B3" value="7.7" lower_limit="7.4" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endothelial Progenitor Cells Number</title>
          <units>EPC/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="24.0" upper_limit="58.2"/>
                    <measurement group_id="B2" value="37.5" lower_limit="25.0" upper_limit="59.8"/>
                    <measurement group_id="B3" value="38" lower_limit="24.2" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in the Endothelial Progenitor Cell (EPC) Number</title>
        <description>The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.</description>
        <time_frame>V0, V2 (month 4), V4 (12 month)</time_frame>
        <population>Intention to treat (ITT) analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Vildagliptin &amp; Metformin</title>
            <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Vildagliptin: 100 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide &amp; Metformin</title>
            <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Glibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the Endothelial Progenitor Cell (EPC) Number</title>
          <description>The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.</description>
          <population>Intention to treat (ITT) analysis</population>
          <units>EPC/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V2 (4 month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="27.0" upper_limit="65.0"/>
                    <measurement group_id="O2" value="36" lower_limit="23.0" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 (12 month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="29.7" upper_limit="67"/>
                    <measurement group_id="O2" value="32" lower_limit="22.2" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Generalized linear model (GLM)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>adjustment for baseline value of EPC</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.362</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.695</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in HbA1C Compared to Baseline</title>
        <description>The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months</description>
        <time_frame>V0 (randomization), V2 (month4), V4 (month 12).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vildagliptin &amp; Metformin</title>
            <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Vildagliptin: 100 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Glibenclamide &amp; Metformin</title>
            <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Glibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in HbA1C Compared to Baseline</title>
          <description>The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months</description>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V2 (4 month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="6.4" upper_limit="7.3"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.4" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 (12 month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="6.5" upper_limit="7.3"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.5" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Slope</param_type>
            <param_value>-0.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.358</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Hypoglycemia</desc>
      <group_list>
        <group group_id="E1">
          <title>Vildagliptin &amp; Metformin</title>
          <description>Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Vildagliptin: 100 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Glibenclamide &amp; Metformin</title>
          <description>Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
Glibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>At each study visit side effects were systematically investigated and patients were asked to contact the centre in case of adverse events.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof.ssa Ivana Zavaroni</name_or_title>
      <organization>Azienda ospedaliero-universitaria di Parma</organization>
      <phone>+390521033306</phone>
      <email>ivana.zavaroni@unipr.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

